HighVista Strategies LLC Sells 790 Shares of argenex SE $ARGX

HighVista Strategies LLC trimmed its holdings in shares of argenex SE (NASDAQ:ARGX) by 24.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,415 shares of the company’s stock after selling 790 shares during the quarter. HighVista Strategies LLC’s holdings in argenex were worth $1,331,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in ARGX. Goldman Sachs Group Inc. increased its position in shares of argenex by 14.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock valued at $99,886,000 after purchasing an additional 21,805 shares during the last quarter. Amundi grew its position in argenex by 8.1% during the 1st quarter. Amundi now owns 6,351 shares of the company’s stock worth $3,747,000 after acquiring an additional 478 shares during the last quarter. Voya Investment Management LLC increased its stake in argenex by 5.2% in the 1st quarter. Voya Investment Management LLC now owns 14,905 shares of the company’s stock worth $8,822,000 after purchasing an additional 735 shares during the period. Royal Bank of Canada grew its holdings in shares of argenex by 0.9% in the first quarter. Royal Bank of Canada now owns 38,306 shares of the company’s stock worth $22,673,000 after purchasing an additional 353 shares during the last quarter. Finally, Aberdeen Group plc raised its holdings in argenex by 28.8% during the 2nd quarter. Aberdeen Group plc now owns 70,293 shares of the company’s stock valued at $38,747,000 after buying an additional 15,703 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Truist Financial raised their target price on argenex from $700.00 to $918.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. Wolfe Research reaffirmed a “peer perform” rating on shares of argenex in a research note on Monday, November 24th. Jefferies Financial Group set a $818.00 price objective on shares of argenex and gave the stock a “buy” rating in a report on Tuesday, August 26th. Deutsche Bank Aktiengesellschaft cut argenex from a “buy” rating to a “hold” rating in a research report on Thursday, September 11th. Finally, Evercore ISI lifted their price target on shares of argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $917.39.

argenex Price Performance

Shares of NASDAQ:ARGX opened at $890.11 on Thursday. argenex SE has a 1 year low of $510.05 and a 1 year high of $934.62. The stock’s fifty day moving average price is $859.76 and its 200-day moving average price is $713.03. The company has a market cap of $54.80 billion, a P/E ratio of 38.22, a PEG ratio of 0.89 and a beta of 0.37.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, October 30th. The company reported $4.40 earnings per share for the quarter, topping the consensus estimate of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The business had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.07 billion. On average, sell-side analysts anticipate that argenex SE will post 3.13 earnings per share for the current year.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.